Company Overview
| Stock Name | Mabpharm-B |
|---|---|
| Stock Code | 02181 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 专注于治疗癌症和自身免疫性疾病的新药及生物类似药的研发和生产 |
| Listing Date | 2019-05-31 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 泰州中国医药城口泰路西侧陆家路东侧G79幢 |
| Business Address (Hong Kong) | 新界沙田香港科学园二期尚湖楼7楼713单位 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | mabpharm.cn |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 1.50 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2019-05-20 to 2019-05-24 |
| Global Offering Shares | 783,580,000 shares |
| HK Public Offer Shares (Initial) | 78,358,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 705,222,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 4,124,080,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 16.7% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,175,370,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 1.91B |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +409% |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不适用(公司处于亏损状态) |
| Profit/Loss Status | 亏损约人民币149.8百万元 |
| Period-End Cash Balance | 人民币198.2百万元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2017 | 2018 |
|---|---|---|
| Revenue | 4,798 | 24,059 |
| Cost of sales | -307 | -12,507 |
| Administrative expenses | -24,900 | -42,128 |
| Net finance costs | -3,328 | -4,481 |
| Profit before tax | -47,706 | -152,593 |
| Income tax expense | 0 | -2,834 |
| Profit for the year | -47,706 | -149,759 |
| Profit attributable to owners | -31,064 | -124,883 |
Balance Sheet
| Item | 2017 | 2018 |
|---|---|---|
| Cash and cash equivalents | 76,443 | 198,195 |
| Inventories | 36,319 | 27,551 |
| Total current assets | 154,935 | 260,753 |
| Total current liabilities | 70,853 | 156,450 |
| Total equity | 153,289 | 249,572 |
| Equity attributable to owners | 99,813 | 249,572 |
| Interest-bearing borrowings | 75,000 | 105,000 |
Cash Flow Statement
| Item | 2017 | 2018 |
|---|---|---|
| Net cash from operating activities | -65,122 | -61,874 |
| Net cash from investing activities | -13,597 | -82,706 |
| Net cash from financing activities | 16,897 | 256,819 |
| Net increase in cash | -61,822 | 112,239 |
| Depreciation of PP&E | 10,080 | 11,716 |
| Purchase of PP&E | -13,129 | -49,787 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 1.21 |
|---|---|
| First Day Open | HK$ 1.5 |
| First Day Change | -19.33% |
| First Day Volume | 167506000.0 |
| First Day Turnover | 215606000.0 |
| Use of Proceeds | 1、約70.1%或748.7百萬港元將用于我們的核心候選產品CMAB007、CMAB008及CMAB009;
2、約20.1%或214.7百萬港元將用于我們其他候選產品的研發活動;
3、約9.8%或104.7百萬港元將用作營運資金及其他一般企業用途。 |
Underwriting Syndicate
Sole Sponsor (1)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Overall Coordinators (1)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Joint Bookrunners (1)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 三生制药 | 196,227,000 HKD | — | 16.69% | — | 6 months | 2019-11-30 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 焦树阁 | — |
| Company Secretary | 李云峰、曾浩贤 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 控股股东郭建军先生(透过Asia Mabtech及United Circuit合共持有约54.00%),CDH PE持有18.00%,FH Investment持有5.18% |
|---|




